New drug duo tested for Tough-to-Treat blood cancer

NCT ID NCT05646836

Summary

This early-stage study is testing whether two new drugs, XmAb24306 and cevostamab, can be safely given together to people with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial will enroll about 90 patients who have already tried at least three different types of therapies. Researchers will monitor side effects closely and check if the drug combination shows any signs of helping control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • Asan Medical Center - PPDS

    Seoul, 05505, South Korea

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Evangelismos General Hospital of Athens

    Athens, 106 76, Greece

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, 46026, Spain

  • Oslo University Hospital Rikshospitalet

    Oslo, N - 0424, Norway

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Rabin Medical Center-Beilinson Campus

    Petah Tikva, 4941492, Israel

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Severance Hospital, Yonsei University

    Seoul, 03722, South Korea

  • Sygehus Lillebaelt - Vejle Sygehus

    Vejle, 7100, Denmark

  • Tel Aviv Sourasky Medical Center PPDS

    Tel Aviv, 64239, Israel

  • University of Athens, Hematological Clinic,

    Athens, 115 28, Greece

Conditions

Explore the condition pages connected to this study.